Technical Analysis for MESO - Mesoblast Limited
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Historical MESO trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bullish Signal Line Cross | Bullish | 0.00% | |
NR7 | Range Contraction | 0.00% | |
NR7-2 | Range Contraction | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -0.58% | |
NR7 | Range Contraction | -0.58% | |
Inside Day | Range Contraction | -0.58% | |
Up 3 Days in a Row | Strength | -0.58% | |
Oversold Stochastic | Weakness | -0.58% | |
20 DMA Resistance | Bearish | 0.59% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.59% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
10 DMA Support | 1 day ago |
Fell Below 10 DMA | 1 day ago |
Down 1% | 1 day ago |
Non-ADX 1,2,3,4 Bearish Retracement Entry | 1 day ago |
Fell Below Previous Day's Low | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 09/27/2019
Mesoblast Limited Description
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative therapeutic cell-based products in Australia, the United States, and Singapore. The company is developing therapeutic products using its proprietary technology platforms, which include mesenchymal lineage adult stem cells (MLCs) to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. Its lead product candidates comprise MPC-150-IM for congestive heart failures; MPC-06-ID to treat chronic lower back pain due to moderate degenerative disc diseases; MSC-100-IV for the treatment of steroid refractory acute graft versus host diseases (GVHDs); and MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy. The company is also developing JR-031 for pediatric and adult GVHDs; MPC-25-IC, which is in Phase II clinical trial to treat acute cardiac ischemia; MPC-25-Osteo that has been completed Phase II clinical trial for the treatment of spinal fusion; and MPC-CBE, which is in Phase III clinical trial to treat bone marrow transplantations. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its MPCs for cardiovascular diseases and neurologic conditions. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Pharmaceutical Industry Bone Stem Cells Hematology Therapeutic Product Proprietary Technology Rheumatoid Arthritis Cardiovascular Disease Therapeutic Products Heart Failure Spine Vascular Diseases Cardiovascular Diseases Pharmaceutical Industries Transplantation Bone Marrow Diabetic Nephropathy Adult Stem Cell Cell Product Ischemia Back Pain Congestive Heart Failure Host Disease Skeletal Disorders Spinal Fusion Teva Pharmaceutical Industries Graft Versus Host Disease Mesoblast Host Diseases Inflammatory Conditions Regenerative Biomedicine Bone Marrow Transplantation Cardiac Diseases Degenerative Disc Disease Musculoskeletal Disorders
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 21.28 |
52 Week Low | 4.1 |
Average Volume | 301,858 |
200-Day Moving Average | 12.40 |
50-Day Moving Average | 9.32 |
20-Day Moving Average | 8.85 |
10-Day Moving Average | 8.43 |
Average True Range | 0.41 |
ADX | 17.98 |
+DI | 15.25 |
-DI | 21.90 |
Chandelier Exit (Long, 3 ATRs ) | 8.62 |
Chandelier Exit (Short, 3 ATRs ) | 9.34 |
Upper Bollinger Band | 9.84 |
Lower Bollinger Band | 7.85 |
Percent B (%b) | 0.33 |
BandWidth | 22.49 |
MACD Line | -0.29 |
MACD Signal Line | -0.30 |
MACD Histogram | 0.01 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 8.85 | ||||
Resistance 3 (R3) | 8.85 | 8.73 | 8.79 | ||
Resistance 2 (R2) | 8.73 | 8.65 | 8.73 | 8.78 | |
Resistance 1 (R1) | 8.62 | 8.59 | 8.56 | 8.62 | 8.76 |
Pivot Point | 8.51 | 8.51 | 8.48 | 8.51 | 8.51 |
Support 1 (S1) | 8.39 | 8.42 | 8.34 | 8.40 | 8.26 |
Support 2 (S2) | 8.28 | 8.37 | 8.28 | 8.24 | |
Support 3 (S3) | 8.17 | 8.28 | 8.23 | ||
Support 4 (S4) | 8.17 |